CONTINUING EDUCATION, 1 CE Credit – $9.99, 1 Hour, General Knowledge, Level 1, Release date: October 2007, Expiration date: October 31, 2012

merchant processing services

Merchant Processing Services

 
 
 
 
 
 
 
 
 
 
 

Novartis to Acquire 25 Percent 
Minority Stake in Alcon from Nestlé

Nestlé S.A. and Novartis AG announced today that they have reached an agreement pursuant to which Nestlé will sell 74 million of its shares of Alcon, Inc. (NYSE:ACL) common stock to Novartis in a cash transaction at a price of $143.18 per share. Once consummated, Novartis would own a minority stake in Alcon of approximately 25 percent of Alcon's outstanding shares, while Nestlé would remain Alcon's majority shareholder with approximately 52 percent of Alcon's outstanding shares. 

Nestlé and Novartis also announced that the agreement contains put and call option rights on the remaining Alcon shares owned by Nestlé, which commence on January 1, 2010 and expire on July 31, 2011. As outlined by the two parties, these rights grant (i) Novartis a call option to buy Nestlé's remaining Alcon shares at a fixed price of $181 per share and (ii) Nestlé a put option to sell its remaining Alcon shares to Novartis at the lower of Novartis's call price of $181 per share or at a 20.5 percent premium above the market price of Alcon shares, which will be calculated as the average price of Alcon shares during the week preceding the exercise date of the put option.

The agreement also provides for the expansion of the Alcon board of directors from eight to ten members, with one of the additional members designated by Nestlé and one designated by Novartis. The nominees for these additional board seats are James Singh, who is currently Nestlé's executive vice president and chief financial officer, and Daniel Vasella, M.D., who is chairman and chief executive officer of Novartis. Shareholders will vote on whether to expand the Alcon board and to elect these nominees at Alcon's upcoming Annual General Meeting which will be held on May 6, 2008 in Zug, Switzerland. Alcon distributed proxy materials to its shareholders on April 2, 2008, and it will distribute a new proxy form to shareholders incorporating these additional items. 

"I welcome Novartis as a minority investor, and I believe the agreement validates Alcon's leadership and bright future in the attractive and growing eye care market," said Cary Rayment, Alcon's chairman, president and chief executive officer. "It is also a testament to all of our employees who have been responsible for making Alcon the global leader in the eye care market."

The purchase and sale transaction is subject to regulatory approvals.

JANUARY ISSUE FEATURES

Fabulous Sunwear
Impress your patients in the new year with all the latest and greatest styles in sunwear...

Strategy for Independents
A proactive strategy for independents is crucial in this increasingly competitive environment...

New Year's Resolutions
Get your practice off to a good start in 2012 by fulfilling all your optical resolutions...
Knowing Your Limits
An anecdote that illustrates the importance of trusting your instincts & standing your ground...
Digital or Free Form?
It's important that ECPs understand differences between digital and free form lenses...
Digital Media Importance
Facebook, YouTube, and Twitter are all free and essential in promoting optical dispensaries...
EyeCare Industry Mover and Shakers
See who's shaking up the eye care industry...
Projecting Value 
Teach your patients the value of your products and services and they will return the favor...
Great Artist's Vision Problems
Some of our greatest artist's works may have been a result of visual ailments...
Unique Case Study
A unique case in which all three of the “O’s” worked together to help a troubled patient...

Hope for the New Year
Find the right marketing/pricing strategy, and get the New Year off to the right start...

EyeVertise
Customize your website and watch your eyecare practice grow...

FAN US ON FACEBOOK

Send press releases to: editor@ecpmag.com
 
 
 
© All content is the property of ECPMag.com™ OptiCourier Ltd. &  assoc. vendors. Website Powered and Developed by EyeVertise.com - 847.202.1411 | email